In addition, a genome-wide CRISPR activation screen revealed that fibroblast growth factor receptor 1 (FGFR1) signaling could compensate NRG1–HER3 axis function to rescue NRG1-deficient circulating tumor cells (CTCs). Here, FGFR1 is linked to neoplasm.